The LAG-3 Market has moved from a niche immunology focus to a key area in oncology, immuno-oncology combinations, and autoimmune disease research. Interest beyond PD-1/PD-L1 checkpoints has grown, supported by stronger biological insights, expanding clinical pipelines, and data suggesting better outcomes when LAG-3 modulation is used with other therapies. Scientific and clinical backgroundLAG-3...